PharmaTimes1d
Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...
PharmaTimes2d
Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy
Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...
PharmaTimes4d
Imfinzi receives NICE recommendation for lung cancer treatment
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
PharmaTimes4d
Poolbeg Pharma presents positive results for POLB 001
The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...